At a glance
ClinicalIndex Comparison RecordN/ACompleted· 79 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cystic Fibrosis Related Bone Disease: the Role of CFTR
In Brief
An observational study for Cystic Fibrosis Related Bone Disease. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether ivacaftor, a recently FDA-approved CFTR potentiator, improves bone micro-architecture and strength in patients with cystic fibrosis with at least one G551D CFTR mutation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis Related Bone Disease
CountriesUnited States
CollaboratorsBoston Children's Hospital
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionMay 2018
Study CompletionFeb 2020
TodayJul 2026
First PostedMar 9, 2012
Enrollment StartApr 1, 2012
Primary CompletionMay 1, 2018
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 14.3 years ago